Polysaccharide with hypoglycemic effect and preparation method thereof
By extracting and processing polysaccharides and their degradation products from the seeds of the seeds of the seeds, the polysaccharides with lowering blood sugar was prepared, which solved the problems of the side effects of existing drugs and limited therapeutic effects, and achieved effective blood sugar in cell and mouse models Regulation and safety, providing a more effective natural anti-glycemic drug.
Patent Information
- Application Number
- CN202411116324.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-15
AI Technical Summary
Existing anti-glycemic drugs may be accompanied by serious side effects during long-term use and have limited effect on the treatment of type 2 diabetes. Finding more effective and safer natural source anti-glycemic drugs has become an important scientific issue.
By extracting polysaccharides and their degradation products from the seeds of the water chestnut, the process of leaching and removing proteins, ultrasonic treatment and dialysis, etc., prepare the water chestnut polysaccharides and their degradation products with blood sugar-lowering effects and are used to inhibit α-glucosidase , regulate blood sugar levels.
Gorgoferol and its degradation products have an inhibitory effect on α-glucosidase, which can increase glucose consumption in insulin-resistant cell models, reduce the content of glycated serum protein, improve blood sugar regulation ability, and significantly reduce blood sugar levels in mouse models and Cytokine IL-2 and IL-6 levels.
Smart Images

Figure CN118955758A_ABST
Abstract
Description
Technical Field
[0001] The invention provides a method for preparing euryale polysaccharide with blood sugar lowering effect and its degradation product, belonging to the technical field of natural plant polysaccharide. Background Art
[0002] Diabetes is a serious chronic disease and one of the most pressing health issues in the world. Diabetes occurs when there is a defect in the regeneration or function of insulin in the body. The disease is caused by a combination of genetic, autoimmune and environmental factors. At the same time, the prevalence of diabetes is further exacerbated by the rapid increase in related risk factors such as overweight and obesity. Diabetes is not only a threat to health, but also a major factor in disability and life expectancy. The complexity and serious impact of this disease make it a challenge that needs to be addressed in today's medical and public health fields. Therefore, targeted prevention of non-communicable diabetes is crucial to the development and productivity of the country, in the context of a comprehensive understanding of the current and future disease burden.
[0003] Diabetes can be divided into type 1 and type 2 diabetes, of which type 2 diabetes accounts for nearly 90% of diabetes patients worldwide. At present, different modes of pharmacological methods such as stimulating insulin release, increasing glucose transport activity, inhibiting gluconeogenesis and reducing intestinal glucose absorption have been used to control diabetes. Oral hypoglycemic drugs such as biguanides, thiazolidinediones and glucosidase inhibitors are currently the main drugs for the treatment of type 2 diabetes. However, these drugs can only maintain blood sugar control, and long-term use may be accompanied by serious side effects. Therefore, finding and studying more effective and safer natural hypoglycemic drugs has become an important scientific issue at present.
[0004] Gorgon fruit (Euryale ferox Salisb.) is the mature, dried seed kernel of the annual aquatic plant of the genus Gorgon in the Nymphaeaceae family. Gorgon fruit can be used for medicine and food. Modern medical research has confirmed that it contains compounds such as polysaccharides and polyphenols, and exhibits biological activities such as antioxidant, anti-fatigue, hypoglycemic, antibacterial and gastric mucosal protection. The medicinal and health value of Gorgon fruit currently mainly remains in the field of traditional medicine, and there are relatively few studies on the identification and efficacy of the active ingredients in Gorgon fruit. Although research on the hypoglycemic effect of Gorgon fruit has been discovered, there has been no report on the activity of Gorgon fruit in degrading polysaccharides to reduce blood sugar. Therefore, the in-depth development and utilization of Gorgon fruit resources can provide new ideas for the development of the industry and human health. Summary of the invention
[0005] The present invention provides a polysaccharide with hypoglycemic effect and a preparation method thereof, the purpose of which is to solve the problems in the background technology, reduce the content of glycosylated serum protein, and have good blood sugar regulating ability.
[0006] The present invention is achieved through the following technical solutions:
[0007] On one hand, the present invention provides a polysaccharide with hypoglycemic effect, wherein the polysaccharide is a natural plant polysaccharide, specifically, euryale polysaccharide and euryale polysaccharide degradation product.
[0008] Another aspect of the present invention provides a method for preparing a polysaccharide having a hypoglycemic effect, wherein the polysaccharide is a method for preparing a polysaccharide of Euryale ferox or a degradation product of the polysaccharide of Euryale ferox, and specifically comprises the following steps:
[0009] (1) Extraction of Gorgon Fruit Polysaccharide: A certain amount of Gorgon Fruit kernels are dried, crushed by a grinder, and sieved. Anhydrous ethanol is added in a certain solid-liquid ratio and extracted in a water bath for a certain period of time. The residue is filtered and the filter residue is taken. The above operation is repeated twice. The filter residue is dried in a forced air oven at a certain temperature, deionized water is added, and the mixture is extracted for a certain period of time. The supernatant is obtained by centrifugation, concentrated, and a certain volume of anhydrous ethanol is added. The mixture is stirred for a while and allowed to stand overnight. After centrifugation, the precipitate is completely dissolved in deionized water to obtain a Gorgon Fruit Polysaccharide Extract.
[0010] (2) Preparation of Euryale polysaccharide protein removal: The Euryale polysaccharide extract in step (1) and Sevag reagent are mixed in a ratio of 1:3, shaken and mixed, and the polysaccharide solution is obtained after centrifugation. The above operation is repeated several times until no protein appears in the middle layer, and the Euryale polysaccharide solution is concentrated by vacuum rotary evaporation, and the organic solvent is removed and then placed in a dialysis bag for dialysis. After freeze-drying, Euryale polysaccharide (ESPS) is finally obtained.
[0011] (3) Preparation of degradation product of Euryale polysaccharide: dry ESPS powder was dissolved in deionized water to prepare a polysaccharide solution with a concentration of 3 to 11 mg / mL, 5 to 9% of 30% hydrogen peroxide was added, the temperature was adjusted to 45 to 85°C, the reaction was carried out at an ultrasonic frequency of 40 kHz for 1 to 3 h, and then cooled to room temperature, dialyzed with ultrapure water in a 3.5 KDa dialysis bag for 48 to 72 h, rotary concentrated and evaporated, anhydrous ethanol was added, and the solution was allowed to stand at 4°C for precipitation overnight, the precipitate was centrifuged, deionized water was added to completely dissolve the precipitate, and finally lyophilized to obtain the degradation product of Euryale polysaccharide (T-ESPS).
[0012] Furthermore, in the step (1), the product is pulverized by a pulverizer and passed through a 40-100 mesh sieve, and anhydrous ethanol is added at a solid-liquid ratio of 1:10-1:60 g / mL and extracted in a 90° C. water bath for 2-3 hours.
[0013] Furthermore, the filter residue in step (1) is dried in a blast oven at 60-80° C., 70-90 times of deionized water is added, and the mixture is extracted at 90° C. for 3-5 hours.
[0014] Furthermore, after concentration in step (1), 4 to 5 times the volume of anhydrous ethanol is added, stirred for a while, and allowed to stand at 4° C. overnight. After centrifugation, 4 to 5 times the volume of deionized water is added to the precipitate to completely dissolve it.
[0015] Furthermore, in the step (2), the Euryale ferox polysaccharide extract in the step (1) and the Sevag reagent are mixed in a ratio of 1:3.
[0016] Furthermore, in the step (3), the dried ESPS powder is dissolved in deionized water to prepare a polysaccharide solution with a concentration of 3 to 11 mg / mL, 5 to 9% of 30% hydrogen peroxide is added, the temperature is adjusted to 45 to 85° C., the solution is reacted at an ultrasonic frequency of 40 Khz for 1 to 3 hours, and then cooled to room temperature.
[0017] Furthermore, in step (3), the solution is dialyzed with ultrapure water using a 3.5 KDa dialysis bag for 48 to 72 hours, concentrated and evaporated by rotary evaporation, anhydrous ethanol is added, and the solution is allowed to stand at 4° C. for precipitation overnight.
[0018] Furthermore, the evaluation index for lowering blood sugar is α-glucosidase.
[0019] In another aspect, the present invention provides a use of a polysaccharide having a blood sugar lowering effect, specifically, euryale polysaccharide and euryale polysaccharide degradation products for use in the fields of medicine, health care products and food.
[0020] The present invention has the following advantages: the Euryale polysaccharide and its degradation products have an inhibitory effect on α-glucosidase, and can increase the glucose consumption of cells in an insulin-resistant HepG2 (IR-HepG2) cell model. In a validation experiment of an animal experimental model of type 2 diabetic mice, the present invention can reduce the content of glycosylated serum protein, has good blood sugar regulation ability, and can effectively improve the levels of mouse serum cytokines IL-2 and IL-6. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The present invention will be further described below in conjunction with embodiments with reference to the accompanying drawings.
[0022] Figure 1 Schematic diagram of the inhibitory effect of ESPS and T-ESPS on α-glucosidase.
[0023] Figure 2 High performance gel permeation chromatograms of ESPS and T-ESPS (including 2a and 2b).
[0024] Figure 3 The ion chromatograms of monosaccharide standards, ESPS and T-ESPS (including 3a, 3b, and 3c).
[0025] Figure 4 Schematic diagram of the toxicity evaluation of ESPS and T-ESPS on HepG2 cells and their effects on glucose consumption in IR-HepG2 cells (including 4a and 4b).
[0026] Figure 5Schematic diagram of the effects of ESPS and T-ESPS on blood glucose-related levels, glycated serum proteins and cytokines in T2DM mice (including 5a, 5b, 5c, and 5d). DETAILED DESCRIPTION
[0027] The following is a detailed description of an embodiment of the present invention in conjunction with the accompanying drawings: This embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation method and a specific operation process are given, but the protection scope of the present invention is not limited to the following embodiments.
[0028] A polysaccharide with hypoglycemic effect and a preparation method thereof, wherein the preparation process is as follows: euryale seed kernels → water extraction and alcohol precipitation → euryale polysaccharide extract → protein removal → rotary evaporation concentration → freeze drying to obtain the euryale polysaccharide (ESPS) of the present invention → hydrogen peroxide combined with ultrasound → dialysis to remove impurities → rotary evaporation concentration → alcohol precipitation → water dissolution → freeze drying to obtain the euryale polysaccharide degradation product (T-ESPS) of the present invention → ion chromatography to determine the monosaccharide composition of ESPS and T-ESPS.
[0029] The specific steps are:
[0030] (1) Extraction of Gorgon Fruit Polysaccharide: Take a certain amount of Gorgon Fruit kernels and dry them, grind them with a grinder, and then pass them through a 40-100 mesh sieve. Add anhydrous ethanol at a solid-liquid ratio of 1:10-1:60 g / mL and extract them in a 90°C water bath for 2-3 hours. Filter and take the filter residue. Repeat the above operation twice. Dry the filter residue in a 60-80°C forced air oven, add 70-90 times deionized water, and extract at 90°C for 3-5 hours. Centrifuge and take the supernatant. After concentration, add 4-5 times the volume of anhydrous ethanol, stir for a while, and stand at 4°C overnight. After centrifugation, add 4-5 times the volume of deionized water to completely dissolve the precipitate to obtain a Gorgon Fruit Polysaccharide Extract.
[0031] (2) Protein removal from Euryale polysaccharide: The Euryale polysaccharide extract and Sevag reagent were mixed at a ratio of 1:3, oscillated and mixed, and the polysaccharide solution was obtained after centrifugation. The above operation was repeated several times until no protein appeared in the middle layer. The Euryale polysaccharide solution was concentrated by vacuum rotary evaporation, the organic solvent was removed, and the solution was dialyzed in a dialysis bag. After freeze drying, Euryale polysaccharide (ESPS) was finally obtained.
[0032] (3) Preparation of degradation products of Euryale polysaccharide: dry ESPS powder was dissolved in deionized water to prepare a polysaccharide solution with a concentration of 3-11 mg / mL, 5-9% of 30% hydrogen peroxide was added, the temperature was adjusted to 45-85°C, the reaction was carried out at an ultrasonic frequency of 40 Khz for 1-3 hours, and then cooled to room temperature, and dialyzed with ultrapure water in a 3.5 KDa dialysis bag for 48-72 hours. Rotary concentration and evaporation were performed, anhydrous ethanol was added, and the solution was allowed to stand at 4°C for precipitation overnight, the precipitate was centrifuged, deionized water was added to completely dissolve the precipitate, and finally lyophilized to obtain degradation products of Euryale polysaccharide (T-ESPS).
[0033] (4) Determination of α-glucosidase inhibition rate: prepare 1U / mL α-glucosidase enzyme solution, 5mmol / mL PNPG solution, 0.1mol / L sodium carbonate stop solution, different concentrations of acarbose solution, and different concentrations of test solution. Add 40μL of polysaccharide solution and enzyme solution to each drug reaction group; add 40μL of polysaccharide solution and pbs solution to the drug control group; add 40μL of deionized water and enzyme solution to the blank reaction group; add 40μL of deionized water and pbs buffer to the blank control group. Place each reaction group in a 37℃ constant temperature incubator for 15 minutes, and then add 60μL of pre-prepared PNPG solution. Continue to put the reaction system back into the 37℃ constant temperature incubator for incubation for 25 minutes, then add 60μL of NaCO3 solution, and the reaction ends. Finally, measure the absorbance value at a wavelength of 405nm. Calculate according to formula (1-1):
[0034]
[0035] A a ——Absorbance value of drug response group
[0036] A b ——Absorbance value of blank reaction group
[0037] A c ——Absorbance value of blank control group
[0038] A d ——Absorbance value of drug control group
[0039] (5) Molecular weight determination: The molecular weights of ESPS and T-ESPS were determined by high performance gel permeation chromatography (HPGPC).
[0040] (6) Determination of monosaccharide composition: Referring to the method of (Hu Datong. Isolation, purification, structural characterization and biological activity research of spatholobiaceae polysaccharide [D]. Shandong University of Traditional Chinese Medicine, 2022.), the monosaccharide composition of ESPS and T-ESPS was determined by ion chromatography.
[0041] (7) Determination of cytotoxicity of ESPS and T-ESPS: Cytotoxicity is reflected by cell survival rate. HepG2 cells in the logarithmic phase were inoculated in a 96-well plate. After culturing for 24 hours, the supernatant was removed, the cells were washed with PBS, and the culture medium containing ESPS and T-ESPS was added for 12 hours. The supernatant was removed and washed twice with PBS. The culture medium containing CCK-8 was added and continued to be cultured for 4 hours. The absorbance value at 570 nm was measured. The cell survival rate was calculated by formula (1-2):
[0042]
[0043] A s is the absorbance value at 570 nm of the experimental group, which includes cell culture medium and CCK-8 solution configured with different concentrations of polysaccharides.
[0044] A c is the absorbance value of the blank group at 570 nm, which only includes blank culture medium and CCK-8 solution;
[0045] A b is the absorbance value of the control group at 570 nm, including the culture medium containing cells and CCK-8 solution.
[0046] (8) Determination of glucose consumption in insulin-resistant HepG2 cell model (IR-HepG2): After adding different concentrations of ESPS and T-ESPS solutions (200, 400, 800 and 1000 μg / mL, respectively) to IR-HepG2 cells for 24 h, the glucose (Glu) colorimetric test kit was used to measure the glucose content in the supernatant and the glucose consumption of each group was obtained.
[0047] (9) Determination of fasting blood glucose (FBG): After successful modeling, the FBG value of each mouse was tested regularly every week. Before blood glucose measurement, the mouse needed to fast for 12 hours, then wipe the mouse tail with a 75% alcohol disinfectant cotton pad, and then use a blood collection needle to collect blood through the tail vein, and use a blood glucose meter and matching test strips for measurement.
[0048] (10) Determination of glycosylated serum protein (GSP): The test was performed using a kit according to the instructions of the kit.
[0049] (11) Determination of cytokines in mouse serum: Mouse serum was tested according to the operating instructions of the interleukin-2 (IL-2) and interleukin-6 (IL-6) ELISA kits provided by Beijing Bio-Toda Technology Co., Ltd.
[0050] In order to further understand the content, characteristics and effects of the present invention, the following embodiments are given:
[0051] Example:
[0052] Take a certain amount of Euryale ferox seed kernels and crush them through an 80-mesh sieve. Add anhydrous ethanol at a solid-liquid ratio of 1:10g / mL and extract in a 90℃ water bath for 2h. After filtration, take the filter residue and repeat the above operation twice. The filter residue is dried in a 70℃ blast oven, added with 80 times deionized water, extracted at 90℃ for 4h, centrifuged to take the supernatant, concentrated, added 4 times the volume of anhydrous ethanol, stirred for a while, and stood at 4℃ overnight. After centrifugation, add 4-5 times deionized water to completely dissolve the precipitate to obtain Euryale ferox polysaccharide extract. The above Euryale ferox polysaccharide extract and Sevag reagent are mixed in a ratio of 1:3, shaken and mixed, and the polysaccharide solution is obtained after centrifugation. The above operation is repeated to remove protein. The obtained Euryale ferox polysaccharide solution is concentrated by vacuum rotary evaporation, and the organic solvent is removed and placed in a dialysis bag for dialysis, and freeze-dried to obtain ESPS.
[0053] Take dry ESPS powder and dissolve it in deionized water to prepare a polysaccharide solution with a concentration of 5 mg / mL, add 5-9% 30% hydrogen peroxide, adjust the temperature to 65°C, react at an ultrasonic frequency of 40Khz for 2 hours, and then cool to room temperature. Then dialyze it with ultrapure water in a 3.5KDa dialysis bag for 72 hours. Rotate and concentrate and evaporate, add anhydrous ethanol, let it stand at 4°C overnight, centrifuge to get the precipitate, add deionized water to completely dissolve the precipitate. Finally, freeze-dry to obtain T-ESPS. Figure 1 is the inhibition rate of ESPS and T-ESPS at different concentrations (0.5, 1, 2, 4, 8 mg / mL) on α-glucosidase. The inhibition rates of ESPS and T-ESPS on α-glucosidase are 11.06-40.03% and 16.56-72.29%, respectively. Figure 2 a and Figure 2 b are the molecular weights of ESPS and T-ESPS measured by HPGPC method. The elution times of ESPS and T-ESPS are 32.470min and 38.402min, respectively, which are single peaks. The weight average molecular weights (Mw) of ESPS and T-ESPS are 19078Da and 10904Da, respectively, and the number average molecular weights (Mn) are 18702Da and 10656Da, respectively. The molecular weight results confirm that H2O2 combined with ultrasonic treatment of ESPS is an effective way to prepare T-ESPS. Figure 3 a. Figure 3 b and Figure 3 c are the monosaccharide composition spectra of monosaccharide standard, ESPS and T-ESPS determined by HPGFC. The results show that the monosaccharide composition of ESPS and T-ESPS is glucose.
[0054] HepG2 cells in the logarithmic phase were inoculated in a 96-well plate. After culturing for 24 hours, the supernatant was removed, the cells were washed with PBS, and different concentrations of ESPS and T-ESPS (200, 400, 800, 1000 μg / mL) were added to the culture medium for 12 hours. The supernatant was removed and the cells were washed twice with PBS. After adding the culture medium containing CCK-8 and continuing to culture for 4 hours, the cytotoxicity assay of ESPS and T-ESPS showed that the cell survival rate was higher than 95%. Therefore, the prepared ESPS and T-ESPS were not toxic to HepG2 cells ( Figure 4 a). After adding different concentrations of ESPS and T-ESPS solutions (prepared at 200, 400, 800 and 1000 μg / mL, respectively) to insulin-resistant HepG2 cells (IR-HepG2) for 24 hours, the glucose (Glu) colorimetric test kit was used to measure the glucose consumption of each group. Figure 4 As shown in b. Compared with the normal HepG2 group, the glucose consumption of the IR-HepG2 group was significantly reduced. Compared with the model group, as the administration concentration increased, the glucose consumption of each group increased. Both the ESPS and T-ESPS administration groups had an improvement effect on the glucose consumption of insulin-resistant cells.
[0055] like Figure 5 a shows the changes in fasting blood glucose (FBG) of mice after modeling. After 6 weeks of oral administration of different concentrations of ESPS and T-ESPS and the clinical drug metformin, the blood glucose levels of mice treated with low, medium and high doses of ESPS and T-ESPS were significantly reduced. Figure 5 b reflects the effect of ESPS and T-ESPS on glycosylated serum protein (GSP) in T2DM mice during the experiment. Compared with the diabetes model group, the GSP level was significantly reduced. The serum IL-2 and IL-6 levels of mice in each group were as shown in Figure 5 c and Figure 5 d. After 7 weeks of treatment, the serum IL-2 of mice in the ESPS and T-ESPS treatment groups increased significantly, while the IL-6 decreased significantly. This indicates that the administration of ESPS and T-ESPS effectively improved the blood sugar regulation ability of T2DM mice, improved the serum IL-2 and IL-6 levels of diabetic mice, and had a significant liver-protective effect.
[0056] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A polysaccharide having a blood sugar lowering effect, characterized in that: The polysaccharide is a natural plant polysaccharide, specifically euryale polysaccharide and euryale polysaccharide degradation product. The weight average molecular weight (Mw) of euryale polysaccharide and euryale polysaccharide degradation product are 19078Da and 10904Da respectively, and the number average molecular weight (Mn) is 18702Da and 10656Da respectively.
2. A method for preparing a polysaccharide having a hypoglycemic effect as claimed in claim 1, characterized in that: The polysaccharide is a method for preparing a euryale polysaccharide or a degradation product of a euryale polysaccharide, and specifically comprises the following steps: (1) Extraction of Gorgon Fruit Polysaccharide: A certain amount of Gorgon Fruit kernels are dried, crushed by a grinder, and sieved. Anhydrous ethanol is added in a certain solid-liquid ratio and extracted in a water bath for a certain period of time. The residue is filtered and the filter residue is taken. The above operation is repeated twice. The filter residue is dried in a forced air oven at a certain temperature, deionized water is added, and the mixture is extracted for a certain period of time. The supernatant is obtained by centrifugation, concentrated, and a certain volume of anhydrous ethanol is added. The mixture is stirred for a while and allowed to stand overnight. After centrifugation, the precipitate is completely dissolved in deionized water to obtain a Gorgon Fruit Polysaccharide Extract. (2) Preparation of Euryale polysaccharide protein removal: The Euryale polysaccharide extract in step (1) and Sevag reagent are mixed in a ratio of 1:3, shaken and mixed, and the polysaccharide solution is obtained after centrifugation. The above operation is repeated several times until no protein appears in the middle layer, and the Euryale polysaccharide solution is concentrated by vacuum rotary evaporation, and the organic solvent is removed and then placed in a dialysis bag for dialysis. After freeze-drying, Euryale polysaccharide (ESPS) is finally obtained. (3) Preparation of degradation product of Euryale polysaccharide: dry ESPS powder was dissolved in deionized water to prepare a polysaccharide solution with a concentration of 3 to 11 mg / mL, 5 to 9% of 30% hydrogen peroxide was added, the temperature was adjusted to 45 to 85°C, the reaction was carried out at an ultrasonic frequency of 40 kHz for 1 to 3 h, and then cooled to room temperature, dialyzed with ultrapure water in a 3.5 KDa dialysis bag for 48 to 72 h, rotary concentrated and evaporated, anhydrous ethanol was added, and the solution was allowed to stand at 4°C for precipitation overnight, the precipitate was centrifuged, deionized water was added to completely dissolve the precipitate, and finally lyophilized to obtain the degradation product of Euryale polysaccharide (T-ESPS).
3. The method for preparing a polysaccharide having a hypoglycemic effect according to claim 1, characterized in that: In the step (1), the product is crushed by a crusher and passed through a 40-100 mesh sieve, and anhydrous ethanol is added at a solid-liquid ratio of 1:10-1:60 g / mL and extracted in a 90° C. water bath for 2-3 hours.
4. The method for preparing a polysaccharide having a hypoglycemic effect according to claim 1, characterized in that: In the step (1), the filter residue is dried in a blast oven at 60-80° C., 70-90 times of deionized water is added, and the mixture is extracted at 90° C. for 3-5 hours.
5. The method for preparing a polysaccharide having a hypoglycemic effect according to claim 1, characterized in that: After concentration in step (1), 4 to 5 times the volume of anhydrous ethanol is added, stirred for a while, and allowed to stand at 4° C. overnight. After centrifugation, 4 to 5 times the volume of deionized water is added to the precipitate to completely dissolve it.
6. The method for preparing a polysaccharide having a hypoglycemic effect according to claim 1, characterized in that: In the step (2), the Euryale ferox polysaccharide extract and Sevag reagent in the step (1) are mixed in a ratio of 1:
3.
7. The method for preparing a polysaccharide having a hypoglycemic effect according to claim 1, characterized in that: In the step (3), the dried ESPS powder is dissolved in deionized water to prepare a polysaccharide solution with a concentration of 3 to 11 mg / mL, 5 to 9% of 30% hydrogen peroxide is added, the temperature is adjusted to 45 to 85° C., the solution is reacted at an ultrasonic frequency of 40 Khz for 1 to 3 hours, and then cooled to room temperature.
8. The method for preparing a polysaccharide having a hypoglycemic effect according to claim 1, characterized in that: In the step (3), the ultrapure water is dialyzed using a 3.5 KDa dialysis bag for 48 to 72 hours, the mixture is concentrated and evaporated by rotary evaporation, anhydrous ethanol is added, and the mixture is allowed to stand at 4° C. for precipitation overnight.
9. The method for preparing a polysaccharide having a hypoglycemic effect according to claim 1, characterized in that: The evaluation index for lowering blood sugar is α-glucosidase.
10. A use of the polysaccharide with hypoglycemic effect as claimed in claim 1, characterized in that: Specifically, Euryale gorgonii polysaccharide and degradation products of Euryale gorgonii polysaccharide are used in the fields of medicine, health care products and food.
Citation Information
Cited By
Gordon euryale seed polysaccharide and application thereof in reducing blood sugar
CN122036993A
